Filing Flows › Mangoceuticals (MGRX) › Who owns the stock
Who owns Mangoceuticals (MGRX) stock
18 funds reported Mangoceuticals (MGRX) shares in their latest 13F filings, worth $801K in all. The largest holder is Vanguard Group ($362K). Last quarter 5 funds added to their stakes and 7 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 489,532 | $362K | increase | 2025-12-31 |
| Citadel Advisors LLC | 338,964 | $129K | new | 2026-06-30 |
| XTX Topco | 186,256 | $71K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 156,243 | $59K | decrease | 2026-06-30 |
| Ikarian Capital, LLC | 138,146 | $52K | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 123,041 | $47K | unchanged | 2026-06-30 |
| Vanguard Fiduciary Trust | 57,163 | $22K | unchanged | 2026-06-30 |
| Boothbay Fund Management, LLC | 38,441 | $15K | unchanged | 2026-06-30 |
| Northern Trust | 37,579 | $14K | unchanged | 2026-06-30 |
| StoneX Group | 24,099 | $9K | new | 2026-09-30 |
| ACT Advisors, LLC. | 12,314 | $5K | decrease | 2026-09-30 |
| Goldman Sachs Group | 11,589 | $4K | decrease | 2026-06-30 |
| Sunbelt Securities | 12,000 | $4K | unchanged | 2026-03-31 |
| Csenge Advisory | 10,000 | $4K | unchanged | 2026-06-30 |
| Fortitude Family Office, LLC | 3,074 | $1K | increase | 2026-09-30 |
Mangoceuticals' latest quarter
Mangoceuticals, Q2 2026: revenue $69K (-59% year over year), net loss $1.3M, operating cash flow −$261K. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most MGRX stock?
By the latest 13F filings: Vanguard Group ($362K); Citadel Advisors LLC ($129K); XTX Topco ($71K); Geode Capital Management, LLC ($59K); Ikarian Capital, LLC ($52K).
What is the short interest in MGRX?
91,564 shares were sold short at the 2026-10-15 settlement, -79.13% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.